
Mortality related to neonatal and pediatric fungal infections
Author(s) -
Paolo Manzoni,
Elio Castagnola
Publication year - 2013
Publication title -
reviews in health care
Language(s) - English
Resource type - Journals
eISSN - 2038-6702
pISSN - 2038-6699
DOI - 10.7175/rhc.v4i1s.857
Subject(s) - medicine , antifungal , intensive care medicine , mortality rate , pediatrics , antifungal drugs , dermatology
Thanks to the recent advances in the treatment of neonatal fungal infections, the burden of mortality has been decreasing. However a widely accepted definition is yet to be found, since different thresholds of survival are used in the published trials, and therefore mortality is assumed as occurring 7, 20, 30, or 90 days after treatment, according to the different studies. Regardless of the uncertainty of the definitions, it is more important to know if the patient died with the fungal infection or because of the fungal infection. The new antifungal drugs currently available for neonatal patients were able to increase the survival rates: the attention should, therefore, be focused on the long-term sequelae, which, on the contrary, still affect a big amount of patients. In particular, neurobehavioral and neurosensorial disorders become often evident with age.